Manufactured by Novo Nordisk
FDA-approved for type 2 diabetes, CV risk reduction, and kidney disease. Weekly injection.
See Ozempic savings and coverage →FDA-approved for chronic weight management. Available as weekly injection or daily pill.
See Wegovy savings and coverage →FDA Status
FDA Approved
Route
injection
Approved Indications
Typical Dose Range
0.25mg - 2.4mg weekly
Dosing is determined by your prescribing provider based on your individual needs. Most GLP-1 medications follow a gradual titration schedule, starting at a low dose and increasing over several weeks to reduce side effects.
Branded (Retail)
$1,300/mo
Savings Program
$499/mo
Prices are estimates and may vary by pharmacy, location, and insurance coverage. Contact your provider for accurate pricing.
This is not a complete list of side effects. Talk to your healthcare provider about what to expect and when to seek medical attention.
This site is for educational purposes only and is not medical advice. Always consult a healthcare provider before starting any medication. Full disclaimer
Wegovy is the FDA-approved semaglutide brand for weight loss, available as both a weekly pen and a once-daily pill. See our full pillar covering every coupon, cost breakdown, and access path.
FDA grants Apotex first tentative approval for generic semaglutide injection, potentially cutting Ozempic costs by 40-60% once patent barriers clear.
The DoseNovo Nordisk's oral Wegovy becomes the first FDA-approved GLP-1 pill for weight loss, launching January 2026 at $149/month—offering 16.6% average weight loss without injections.
The DoseStanford researchers found that an existing FDA-approved drug could prevent muscle loss during GLP-1 treatment while maintaining fat loss.
The DoseMajor Lancet study reveals weekly semaglutide significantly reduced heavy drinking days in adults with alcohol use disorder and obesity.
